AMAG Pharmaceuticals CEO William Heiden Elected to PhRMA Board of Directors

WALTHAM, Mass., July 18, 2016 (GLOBE NEWSWIRE) — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, chief executive officer (CEO), has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA).

“The focus of our work at AMAG has been, and continues to be, on improving the lives of patients,” said Mr. Heiden. “I am honored to join PhRMA’s Board and look forward to working with my industry colleagues and the staff of PhRMA to further the pharmaceutical industry’s work in the discovery, development and delivery of important new treatments and cures for patients.”

PhRMA represents the country’s leading innovative biopharmaceutical research and biotechnology companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives.

”I am pleased to welcome William Heiden to PhRMA’s Board,” said Stephen J. Ubl, president and CEO of PhRMA. “His deep knowledge and understanding of the biopharmaceutical research industry will be critical in our continued efforts to promote patient-centered policies that support biomedical innovation.”

Mr. Heiden has served as AMAG’s CEO and a member of its board of directors since May 2012, and has worked in a variety of executive roles across the industry for nearly 30 years. He has served on a number of public and private company boards, and currently serves on the board of Atara Biotherapeutics, Inc. (NASDAQ:ATRA).

About AMAG

AMAG is a biopharmaceutical company focused on developing and delivering important therapeutics, conducting clinical research in areas of unmet need and creating education and support programs for the patients and families we serve. Our products support the health of patients in the areas of maternal health, anemia management and cancer supportive care. Through CBR®, we also help families to preserve newborn stem cells, which are used today in transplant medicine for certain cancers and blood, immune and metabolic disorders, and have the potential to play a valuable role in the ongoing development of regenerative medicine. For additional company information, please visit

AMAG Pharmaceuticals® is a registered trademark of AMAG Pharmaceuticals, Inc.  CBR® is a registered trademark of CBR Systems, Inc.

AMAG Pharmaceuticals, Inc. Contact:

Maryann Cimino
Manager, Corporate Communications & External Affairs

Primary Logo

AMAG Pharmaceuticals, Inc.